Eqis Capital Management, Inc. Intellia Therapeutics, Inc. Transaction History

Eqis Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 24, 2022	BUY	$53.92 - $71.7 $11,323 - $15,057	210 Added 5.08%	4,345 $243,000
Q2 2022 Aug 08, 2022	BUY	$38.49 - $76.21 $159,156 - $315,128	4,135 New	4,135 $214,000
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $178,189 - $363,871	-3,058 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $5,743 - $7,886	57 Added 1.9%	3,058 $362,000
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $245,149 - $327,396	-1,852 Reduced 38.16%	3,001 $403,000
Q2 2021 Aug 12, 2021	SELL	$60.88 - $161.91 $140,511 - $373,688	-2,308 Reduced 32.23%	4,853 $786,000
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $333,630 - $599,232	7,161 New	7,161 $575,000

316

91.7M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.